BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 25023397)

  • 1. Mantle cell lymphoma: taking therapeutic advantage of new insights into the biology.
    Tang T; Martin P
    Curr Hematol Malig Rep; 2014 Sep; 9(3):254-61. PubMed ID: 25023397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel therapies in mantle cell lymphoma: a pathway to chemotherapy-free strategies.
    Nastoupil LJ; Koff JL; Flowers CR
    Oncology (Williston Park); 2013 Oct; 27 Suppl 2():8-12. PubMed ID: 25374999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma.
    Klener P
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31500350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome.
    Zhang L; Pham LV; Newberry KJ; Ou Z; Liang R; Qian J; Sun L; Blonska M; You Y; Yang J; Lin X; Rollo A; Tamayo AT; Lee J; Ford RJ; Zhao X; Kwak LW; Yi Q; Wang M
    Mol Cancer Ther; 2013 Nov; 12(11):2494-504. PubMed ID: 23990113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma.
    Rosich L; Xargay-Torrent S; López-Guerra M; Campo E; Colomer D; Roué G
    Clin Cancer Res; 2012 Oct; 18(19):5278-89. PubMed ID: 22879389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New molecular targets in mantle cell lymphoma.
    Parekh S; Weniger MA; Wiestner A
    Semin Cancer Biol; 2011 Nov; 21(5):335-46. PubMed ID: 21945517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the PI3K/Akt/mTOR signaling pathway by pterostilbene attenuates mantle cell lymphoma progression.
    Yu D; Zhang Y; Chen G; Xie Y; Xu Z; Chang S; Hu L; Li B; Bu W; Wang Y; Xiao W; Sun X; Chang G; Gao L; Qiang S; Wu X; Zhu W; Shi J
    Acta Biochim Biophys Sin (Shanghai); 2018 Aug; 50(8):782-792. PubMed ID: 29961897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel targeted therapeutics for mantle cell lymphoma--what's on the horizon?
    El Halabi L; Ghez D; Ribrag V
    Expert Rev Hematol; 2016 Mar; 9(3):271-81. PubMed ID: 26689790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel agents in mantle cell lymphoma.
    Kumar A
    Curr Oncol Rep; 2015 Aug; 17(8):34. PubMed ID: 26045130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach.
    Bogner C; Peschel C; Decker T
    Leuk Lymphoma; 2006 Feb; 47(2):195-205. PubMed ID: 16321849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
    Kim A; Seong KM; Kang HJ; Park S; Lee SS
    Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic activity of mTOR inhibitors in mantle cell lymphoma: clues but no clear answers.
    Younes A
    Autophagy; 2008 Jul; 4(5):707-9. PubMed ID: 18469512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mantle cell lymphoma-Advances in molecular biology, prognostication and treatment approaches.
    Silkenstedt E; Dreyling M
    Hematol Oncol; 2021 Jun; 39 Suppl 1():31-38. PubMed ID: 34105823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of targeted therapies for mantle cell lymphoma.
    Chang JE; Kahl BS
    Drugs; 2011 Dec; 71(17):2307-26. PubMed ID: 22085387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
    Dawar R; Hernandez-Ilizaliturri F
    Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel agents for mantle cell lymphoma: molecular rational and clinical data.
    Sarkozy C; Ribrag V
    Expert Opin Investig Drugs; 2020 Jun; 29(6):555-566. PubMed ID: 32321318
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale for targeting tumor cells in their microenvironment for mantle cell lymphoma treatment.
    Papin A; Le Gouill S; Chiron D
    Leuk Lymphoma; 2018 May; 59(5):1064-1072. PubMed ID: 28758825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting mTOR in mantle cell lymphoma: current and future directions.
    Smith SM
    Best Pract Res Clin Haematol; 2012 Jun; 25(2):175-83. PubMed ID: 22687453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of B cell antigen receptors in mantle cell lymphoma.
    Fichtner M; Dreyling M; Binder M; Trepel M
    J Hematol Oncol; 2017 Oct; 10(1):164. PubMed ID: 29041946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapies for mantle cell lymphoma: current challenges and a brighter future.
    Skarbnik AP; Smith MR
    Discov Med; 2013 Mar; 15(82):177-87. PubMed ID: 23545046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.